Alexandra Dodd
Psychiatry · Roswell, GANPI 1902330277
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,835 of the $53,957 with a category attached, or 64.6%. 15 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 49.4% of the total. Reporting peaked in 2024 at $37,404 and has fallen 98.6% since, to $536 in 2025. Among psychiatry clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 358 payments — averaging $150.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$27K
- Teva Pharmaceuticals USA, Inc.$24K
- Johnson & Johnson$1K
- Alkermes, Inc.$771
- Otsuka America Pharmaceutical, Inc.$539
- AbbVie$190
- plus $734 from 9 others
What the payments were for
- Consulting fees$7,01313%
- Speaking & faculty fees$34,83565%
- Travel & lodging$2,8125%
- Food & beverage$9,12917%
- Education$1680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 83 | $26,665 |
| Teva Pharmaceuticals USA, Inc. | 155 | $23,825 |
| Johnson & Johnson | 49 | $1,233 |
| Alkermes, Inc. | 19 | $771 |
| Otsuka America Pharmaceutical, Inc. | 19 | $539 |
| AbbVie | 5 | $190 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $172 |
| Indivior Inc. | 7 | $144 |
| Sunovion Pharmaceuticals Inc. | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 5 | $119 |
| Vanda Pharmaceuticals Inc. | 4 | $91 |
| Boston Scientific | 2 | $24 |
| Shire North American Group Inc | 2 | $22 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$25,225
- Austedo XR$17,349
- AUSTEDO$3,803
- LYBALVI$860
- ARISTADA$480
- INVEGA SUSTENNA$359
- ABILIFY MAINTENA$221
- LATUDA$125
- ARISTADA INITIO$120
- SPRAVATO$104
How this compares
$53,957 in reported general payments places this provider in the 95th percentile of 900 psychiatry providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 26 | $213,635 |
| Invega SustennaPaliperidone Palmitate | 30 | $100,281 |
| UzedyRisperidone | 12 | $35,162 |
| Abilify MaintenaAripiprazole | 12 | $34,935 |
| Haloperidol Decanoate | 170 | $11,589 |
| Fluphenazine Hcl | 44 | $8,637 |
| Olanzapine | 181 | $4,684 |
| Divalproex Sodium ErDivalproex Sodium | 43 | $3,127 |
| Benztropine Mesylate | 144 | $1,757 |
| Clozapine | 17 | $1,513 |
| Ziprasidone Hcl | 14 | $1,182 |
| Aripiprazole | 47 | $1,010 |
| Hydroxyzine Hcl | 64 | $829 |
| Haloperidol | 15 | $619 |
| Risperidone | 31 | $612 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $26,665 | $213,63526 claims |
| Johnson & JohnsonInvega Sustenna | $1,233 | $100,28130 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $23,825 | $35,16212 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $539 | $34,93512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Roswell
- Michael RosenRoswell$141K
- Richard WinerRoswell$103K
- Joel KirsonRoswell$99K
- Scot BayRoswell$26K
- Richard PettyLoganville$2.9M
- Ann GrooverCalhoun$1.4M
- Todd AntinDecatur$1M
- Michael BanovMarietta$733K
- Ben HunterBrookhaven$499K
- Joel MorganValdosta$337K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.